{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,5]],"date-time":"2026-08-05T00:08:00Z","timestamp":1785888480393,"version":"3.56.0"},"reference-count":19,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,3,1]],"date-time":"2021-03-01T00:00:00Z","timestamp":1614556800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,3,1]],"date-time":"2021-03-01T00:00:00Z","timestamp":1614556800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,1,25]],"date-time":"2021-01-25T00:00:00Z","timestamp":1611532800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004325","name":"AstraZeneca","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004325","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100010269","name":"Wellcome Trust","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100010269","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Global Antimicrobial Resistance"],"published-print":{"date-parts":[[2021,3]]},"DOI":"10.1016\/j.jgar.2021.01.010","type":"journal-article","created":{"date-parts":[[2021,1,29]],"date-time":"2021-01-29T11:13:04Z","timestamp":1611918784000},"page":"316-320","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":42,"special_numbering":"C","title":["Molecular characterization of clinical isolates of Enterobacterales with elevated MIC values for aztreonam-avibactam from the INFORM global surveillance study, 2012\u20132017"],"prefix":"10.1016","volume":"24","author":[{"given":"Mark","family":"Estabrook","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Krystyna M.","family":"Kazmierczak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark","family":"Wise","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francis F.","family":"Arhin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gregory G.","family":"Stone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel F.","family":"Sahm","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jgar.2021.01.010_bib0005","doi-asserted-by":"crossref","first-page":"1789","DOI":"10.1128\/AAC.04191-14","article-title":"In vitro susceptibility of characterized \u03b2-lactamase-producing strains tested with avibactam combinations","volume":"59","author":"Li","year":"2015","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.jgar.2021.01.010_bib0010","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/j.diagmicrobio.2015.02.003","article-title":"Activities of ceftazidime, ceftaroline, and aztreonam alone and combined with avibactam against isogenic Escherichia coli strains expressing selected single \u03b2-lactamases","volume":"82","author":"Papp-Wallace","year":"2015","journal-title":"Diagn Microbiol Infect Dis"},{"key":"10.1016\/j.jgar.2021.01.010_bib0015","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/j.jgar.2013.01.005","article-title":"Carbapenemases: Partners in crime","volume":"1","author":"Bush","year":"2013","journal-title":"J Glob Antimicrob Resist"},{"key":"10.1016\/j.jgar.2021.01.010_bib0020","series-title":"Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically; approved standard \u2013 tenth edition. CLSI document M07-A10","author":"Clinical and Laboratory Standards Institute","year":"2015"},{"key":"10.1016\/j.jgar.2021.01.010_bib0025","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.00592-18","article-title":"In vitro activity of ceftazidime-avibactam and aztreonam-avibactam against OXA-48-carrying Enterobacteriaceae isolated as part of the International Network for Optimal Resistance Monitoring (INFORM) global surveillance program from 2012 to 2015","volume":"62","author":"Kazmierczak","year":"2018","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.jgar.2021.01.010_bib0030","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.00389-17","article-title":"Unusual Escherichia coli PBP 3 insertion sequence identified from a collection of carbapenem-resistant Enterobacteriaceae tested in vitro with a combination of ceftazidime-, ceftaroline-, or aztreonam-avibactam","volume":"61","author":"Zhang","year":"2017","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.jgar.2021.01.010_bib0035","doi-asserted-by":"crossref","first-page":"1420","DOI":"10.1093\/jac\/dku568","article-title":"Characterization of Escherichia coli NDM isolates with decreased susceptibility to aztreonam\/avibactam: role of a novel insertion in PBP3","volume":"70","author":"Alm","year":"2015","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.jgar.2021.01.010_bib0040","doi-asserted-by":"crossref","first-page":"5704","DOI":"10.1128\/AAC.03057-14","article-title":"Avibactam and class C \u03b2-lactamases: mechanism of inhibition, conservation of the binding pocket, and implications for resistance","volume":"58","author":"Lahiri","year":"2014","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.jgar.2021.01.010_bib0045","article-title":"In vitro selection of aztreonam\/avibactam resistance in dual-carbapenemase-producing Klebsiella pneumoniae","author":"Niu","year":"2019","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.jgar.2021.01.010_bib0050","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.00487-19","article-title":"Structural insights into the inhibition of the extended-spectrum \u03b2-lactamase PER-2 by avibactam","volume":"63","author":"Ruggiero","year":"2019","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.jgar.2021.01.010_bib0055","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.02476-16","article-title":"Exploring the landscape of diazabicyclooctane (DBO) inhibition: avibactam inactivation of PER-2 \u03b2-lactamase","volume":"61","author":"Ruggiero","year":"2017","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.jgar.2021.01.010_bib0060","doi-asserted-by":"crossref","first-page":"2848","DOI":"10.1093\/jac\/dkw248","article-title":"Structural and sequence analysis of class A \u03b2-lactamases with respect to avibactam inhibition: impact of \u03a9-loop variations","volume":"71","author":"Lahiri","year":"2016","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.jgar.2021.01.010_bib0065","doi-asserted-by":"crossref","first-page":"3183","DOI":"10.1128\/AAC.00047-16","article-title":"Identification of novel VEB \u03b2-lactamase enzymes and their impact on avibactam inhibition","volume":"60","author":"Lahiri","year":"2016","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.jgar.2021.01.010_bib0070","doi-asserted-by":"crossref","first-page":"1354","DOI":"10.1093\/jac\/dks079","article-title":"Characterization of \u03b2-lactamase and porin mutants of Enterobacteriaceae selected with ceftaroline\u200a+\u200aavibactam (NXL104)","volume":"67","author":"Livermore","year":"2012","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.jgar.2021.01.010_bib0075","doi-asserted-by":"crossref","first-page":"2942","DOI":"10.1093\/jac\/dku237","article-title":"Activity of avibactam against Enterobacter cloacae producing an extended-spectrum class C \u03b2-lactamase enzyme","volume":"69","author":"Lahiri","year":"2014","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.jgar.2021.01.010_bib0080","doi-asserted-by":"crossref","first-page":"2469","DOI":"10.1093\/jac\/dkx184","article-title":"OXA-427, a new plasmid-borne carbapenem-hydrolysing class D \u03b2-lactamase in Enterobacteriaceae","volume":"72","author":"Bogaerts","year":"2017","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.jgar.2021.01.010_bib0085","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1111\/j.1469-0691.2007.01860.x","article-title":"Extended-spectrum \u03b2-lactamases and the permeability barrier","volume":"14","author":"Martinez-Martinez","year":"2008","journal-title":"Clin Microbiol Infect"},{"key":"10.1016\/j.jgar.2021.01.010_bib0090","doi-asserted-by":"crossref","first-page":"1446","DOI":"10.1093\/cid\/ciz173","article-title":"Antibacterial resistance leadership group, a primer on AmpC \u03b2-lactamases: necessary knowledge for an increasingly multidrug-resistant world","volume":"69","author":"Tamma","year":"2019","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.jgar.2021.01.010_bib0095","doi-asserted-by":"crossref","first-page":"482","DOI":"10.3934\/microbiol.2018.3.482","article-title":"An overview of the antimicrobial resistance mechanisms of bacteria","volume":"4","author":"Reygaert","year":"2018","journal-title":"AIMS Microbiol"}],"container-title":["Journal of Global Antimicrobial Resistance"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2213716521000229?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2213716521000229?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T09:57:55Z","timestamp":1761991075000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2213716521000229"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,3]]},"references-count":19,"alternative-id":["S2213716521000229"],"URL":"https:\/\/doi.org\/10.1016\/j.jgar.2021.01.010","relation":{},"ISSN":["2213-7165"],"issn-type":[{"value":"2213-7165","type":"print"}],"subject":[],"published":{"date-parts":[[2021,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Molecular characterization of clinical isolates of Enterobacterales with elevated MIC values for aztreonam-avibactam from the INFORM global surveillance study, 2012\u20132017","name":"articletitle","label":"Article Title"},{"value":"Journal of Global Antimicrobial Resistance","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jgar.2021.01.010","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 The Author(s). Published by Elsevier Ltd on behalf of International Society for Antimicrobial Chemotherapy.","name":"copyright","label":"Copyright"}]}}